Roche Holding AG (RHHBY)
| Market Cap | 316.68B +25.5% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 19.50 |
| Forward PE | 15.43 |
| Dividend | 0.97 (1.88%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,465,057 |
| Open | 50.44 |
| Previous Close | 51.06 |
| Day's Range | 49.22 - 50.50 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 56.66 (+13.91%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 13.91% from the latest price.
News
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
Quantum Strategy's David Roche expects the US-Iran deal to hold, arguing both Washington and Tehran have strong incentives to keep Iranian oil flowing and avoid political disruption ahead of US midter...
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
Genentech says FDA accepts sBLA for for Lunsumio VELO
Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulation, in c...
FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027
(RTTNews) - Genentech, a unit of Roche Holding AG (RHHBY), announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application (sBLA) for Lunsumio VELO as ...
FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Basel, June 18, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA approves first generic version of Roche's flu drug
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wednesda...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Roche Secures FDA Approval For First PTEN IHC Companion Diagnostic In Prostate Cancer
(RTTNews) - Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug A...
Roche reports FDA approval for prostate cancer companion diagnostic
Roche (RHHBY) announced that the Ventana PTEN RxDx Assay is the first immunohistochemistry companion diagnostic test to receive U.S. Food and Drug Administration approval for determining PTEN protein ...
Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls
The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.
Roche’s global survey highlights urgent need to shift diabetes care from disease treatment to mental wellbeing
[The content of this article has been produced by our advertising partner.] Nearly one in ten people in Hong Kong now live with diabetes, and the city’s burden is growing. An ageing population, shifti...
OraSure announces FDA clearance of Colli-Pee Dx Urine Collection Kit
OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chlamydia trachomatis, Neisseria gonorrhoea...
Genentech granted priority review for Tecentriq Hybreza combination
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, filing for adjuvant Tecentriq and Tecentriq Hybreza in comb...
Roche announces EU IVDR approval of several Ventana label expansions
Roche (RHHBY) announced the European Union In Vitro Diagnostic Regulation, or IVDR, approval of several label expansions for the Ventana MMR RxDx Panel, an immunohistochemistry companion diagnostic te...
Roche 's VENTANA MMR RxDx Panel Gains IVDR Approval Across Multiple Cancer Types
(RTTNews) - Roche (RHHBY) has secured European Union In Vitro Diagnostic Regulation (IVDR) approval for expanded use of its VENTANA MMR RxDx Panel, a companion diagnostic designed to help identify can...
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MM...
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) f...
The Zacks Analyst Blog Highlights Amazon.com, Bank of America, Roche, Oak Valley Bancorp and Ohio Valley Banc
Amazon, Bank of America and Roche are in focus as Zacks highlights growth drivers, expansion plans and product momentum across key businesses.
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Top Stock Reports for Amazon, Bank of America & Roche
Amazon's AI push, sales outlook and diversified revenue streams stand out, while Bank of America and Roche navigate growth drivers and key risks.
Roche Holding AG Transcript: Study update
Phase II results show enicepatide achieved up to 22.7% weight loss at 48 weeks, with strong glycemic improvements and favorable tolerability. Petrelintide demonstrated up to 10.7% weight loss with a placebo-like safety profile, supporting its use for moderate weight loss. Both agents advance to phase III, with combination studies planned.